Combination chemotherapy (high-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer

@article{Bhasin2004CombinationC,
  title={Combination chemotherapy (high-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer},
  author={Richa Bhasin and C. P. Nogeirie},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={11},
  pages={106-107}
}
SummaryTwenty-five patients with non-small cell lung cancer (NSCLC) were treated with high-dose methotrexate with citrovorum factor resuce (HDMTX-CFR), mechlorethamine (HN2) and procarbazine (PCZ). Nineteen patients are evaluable for response. One patient had partial remission which lasted for 11 weeks. Nine patients had stable disease lasting for 6–22 weeks. HDMTX-CFR was well tolerated by these patients but this combination regimen produced very low tumor response rate (5.2%). Addition of HN2… Expand
1 Citations
Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers
TLDR
An overview of the present state of knowledge with regards to complex mechanisms of methotrexate action and its applications as immunosuppressive drug or chemotherapeutic agent in oncological combination therapy is taken. Expand

References

SHOWING 1-10 OF 11 REFERENCES
High-dose methotrexate with citrovorum factor rescue in non-small-cell lung cancer
TLDR
It is concluded that the occasional benefit of high-dose methotrexate with leucovorin rescue at this dose and according to the schedule described for these patients does not warrant further study. Expand
Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer
A Phase 1 study of high‐dose “pulse” methotrexate infusions combined with citrovorum factor “rescue” in advanced lung cancer indicated consistent tumor response in eight patients. A dose scheduleExpand
Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP).
TLDR
Weight loss, performance status, and dominant site of metastases proved to be important prognostic factors and the CAMP regimen was well tolerated; there were only two drug-related deaths, both secondary to infectious complications. Expand
Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
TLDR
High-MTX should now be evaluated in well-designed controlled clinical trials to compare its antitumor activity to that of conventional- or standard-dose MTX regimens in diseases where HD therapy appears to have efficacy. Expand
Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study.
TLDR
The results of this study demonstrate that high-dose methotrexate with citrovorum factor rescue, in the schedule utilized, is not effective in the treatment of patients with non-small cell carcinoma of the lung. Expand
...
1
2
...